Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Phase 1/2 Dose Finding and Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
Protocol ID
PCYC-1146-IM
Disease (Sub Disease)
Chronic Graft Versus Host Disease
Diagnosis Stage
New Diagnosis
Relapse/Refractory
Sponsor
Pharmacyclics LLC.
Collaborators
Janssen Research & Development, LLC
Links
External Registry ≫
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
Part A – 1 to 12 years Part B – 1 to 22 years
International registry ID's
NCT03790332
Back to Registry
Study Title Phase 1/2 Dose Finding and Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
Protocol ID PCYC-1146-IM
Disease (Sub Disease) Chronic Graft Versus Host Disease
Diagnosis Stage New Diagnosis
Relapse/Refractory
Sponsor Pharmacyclics LLC.
Collaborators Janssen Research & Development, LLC
Links https://clinicaltrials.gov/ct2/show/NCT03790332
Trial Status Closed to Recruitment
Trial Open Date 22/01/2019
Study Type Treatment
Phase Phase 1/2
Age Eligibility Part A – 1 to 12 years Part B – 1 to 22 years
International registry ID's NCT03790332